AnxietyNCT05291533
Patient Experiences With Virtual Reality Mindfulness Skills Training
A study testing Virtual Reality (VR) Mindfulness Program in people with Anxiety and Distress, Emotional, run by Weill Medical College of Cornell University at 1 site in United States.
Trial summary
This study aims to assess acceptability and preliminary efficacy of an intervention being administered clinically, a virtual reality (VR) mindfulness program. It is hypothesized that patients will find VR mindfulness an acceptable intervention and that it will reduce symptoms of anxiety. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Anxiety, Distress, Emotional
- What is being tested?
- Virtual Reality (VR) Mindfulness Program
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 29 participants
- Where
- 1 siteUnited States
- Study dates
- 6 May 2022to 18 Aug 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Referred to psychology/neuropsychology
- Identified by treatment team for use of VR mindfulness intervention
- Able to provide informed consent or assent
- Patient is over the age of 18
Who cannot join
- Has not engaged in VR mindfulness intervention.
- Determination by clinical team that patient cannot or would not benefit from participation in VR.
- Reasons may include history of severe motion sickness or seizures, history of destruction of property, visual disturbance, vertigo, and cognitive impairment, delirium, and current or past diagnosis of a psychotic disorder
Trial locations and contacts
1 site in 1 country.
About this study
This study aims to assess acceptability and preliminary efficacy of an intervention being administered clinically, a virtual reality (VR) mindfulness program. It is hypothesized that patients will find VR mindfulness an acceptable intervention and that it will reduce symptoms of anxiety.
Read the detailed description
This pilot study proposes to assess acceptability and preliminary efficacy of an intervention being administered clinically, a virtual reality (VR) mindfulness program. Acceptability and preliminary efficacy will be determined by 1) patient feedback on their satisfaction with the intervention evaluated by the Client Satisfaction Questionnaire-8 (CSQ-8); 2) changes in acute subjective anxiety before and after using the program; 3) changes in subjective relaxation before and after using the program; 4) changes in global anxiety at referral to psychology and just prior to discharge; Any patient on units with access to this VR program who are referred for a psychological evaluation will have the opportunity to engage in the VR intervention.
Overall Design:
This study is an open trial evaluating the acceptability and efficacy of a VR mindfulness program being clinically implemented to address acute anxiety in patients admitted to medical and rehabilitation inpatient units.
VR Mindfulness Program:
Participants referred for a psychological or neuropsychological evaluation will have the opportunity to complete the study. A study staff member who is not the evaluating clinician will approach the patient to inquire about their interest in the study and conduct the informed consent process. Patients are typically referred for a psychological evaluation based on acute anxiety observed by staff or reported by the patient. The evaluating psychologist will collaborate with treatment team to make a clinical determination about whether VR mindfulness is indication (see exclusion criteria below). If it is determined that the patient could benefit from the VR intervention, a VR team member will facilitate the administration of a self-report measure on anxiety (GAD-7), obtain subjective ratings of anxiety and relaxation, and then administer the 5-minute VR mindfulness intervention. After patient's completion of the intervention, the VR team member will repeat the measures of subjective anxiety and relaxation. This procedure will be repeated as-needed (determined by clinical team) or up to three times per week based on patient preference and staff availability. The CSQ-8 will be administered after the patient's first use of VR mindfulness and again the day before discharge, if the patient opted to use repeatedly. The study team will re-administer the GAD-7 on the day prior to the patient's discharge.
Study-specific procedures:
Upon determination by the clinical and study team that a patient is an appropriate candidate for VR mindfulness, the patient will be informed of the opportunity to participate in the study. It will be made clear to the patient that participation in the study is voluntary and will have no impact on their current or future access to care at NYP/WCM. If they agree they will undergo the informed consent process.
Scientific Rationale for Study Design:
This is an open trial to determine acceptability and efficacy of using VR mindfulness to address acute anxiety in varied clinical settings. This intervention is already being implemented clinically, this study seeks to assess acceptability and provide preliminary data on efficacy of this intervention. No control is being used at this time.
- Subject Selection
Subjects will be patients admitted to medical and rehabilitation inpatient units at NYP/WCM.
Recruitment:
Patients are identified by their clinical team during their inpatient admission as appropriate for the VR mindfulness intervention to address acute anxiety.
- Registration Procedures
Subjects will be registered within the WRG-CT as per the standard operating procedure for Subject Registration.
- Study Procedures Upon determination by the treatment team and VR team member that a patient is an appropriate candidate for VR mindfulness, the patient will be informed of the opportunity to participate in the study. It will be made clear to the patient that participation in the study is voluntary and will have no impact on their current or future access to care at NYP/WCM or their ability to participate in the VR mindfulness intervention. If they agree they will undergo the informed consent process.
Measures: Listed in the "Outcome Measures" section
Study intervention:
The study is seeking to evaluate the feasibility and preliminary efficacy of a VR mindfulness intervention. The VR program combines immersive, 3D visuals and audio with mindfulness skills practice. The program is designed to train participants you to calm their bodied and minds and its use is designed to enhance mindfulness practice. VR is a platform that has been used for a variety of applications, including gaming, entertainment, education and training.
Study duration, withdrawal and discontinuation:
Subjects will complete study procedures at least one time, with additional uses determined by need (decided by clinical team) or patient preference (up to three times per week based on staff availability). They will be followed for the duration of their admission. Study participation ends when they are discharged or are no longer eligible to use VR. Participants are free to withdraw from participation in the study at any time upon request.
An investigator may discontinue or withdraw a participant from the study for the following reasons:
- Significant study intervention non-compliance
- If any clinical adverse event (AE) or other medical condition or situation occurs such that continued participation in the study would not be in the best interest of the participant
- If the participant meets an exclusion criterion (either newly developed or not previously recognized) that precludes further study participation
- Participant unable to participate in VR mindfulness intervention
The reason for participant discontinuation or withdrawal from the study will be recorded on the Case Report Form (CRF). Subjects who sign the informed consent form and do not receive the study intervention may be replaced. Subjects who sign the informed consent form and receive the study intervention, and subsequently withdraw, or are withdrawn or discontinued from the study will be replaced.
- Conditions
- Anxiety, Distress, Emotional
- Being tested
- Virtual Reality (VR) Mindfulness Program
- Medical subject headings
- Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Virtual Reality (VR) Mindfulness ProgramOther
The VR program combines immersive, 3D visuals and audio with mindfulness skills practice. The program is designed to train participants you to calm their bodied and minds and its use is designed to enhance mindfulness practice. VR is a platform that has been used for a variety of applications, including gaming, entertainment, education and training.
| Study group | Role | What they receive |
|---|---|---|
| Patients using VR Mindfulness Program | Other | Participants are inpatients on any NYP/WCM unit that use VR mindfulness programs; any patient referred for a psychological or neuropsychological evaluation by their treatment team will have the opportunity to complete the VR program. The study is seeking to evaluate the feasibility and preliminary efficacy of the VR mindfulness intervention. Receives: Other: Virtual Reality (VR) Mindfulness Program |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in composite score on Client Satisfaction Questionnaire-8 (CSQ-8; Attkisson & Zwick, 1982)
An 8-item, empirically validated measure of satisfaction with a clinical program. Scores therefore range from 8 to 32, with lower values indicating lower satisfaction and higher values indicating higher satisfaction.
Measured: Immediately after first intervention (use of VR) and at hospital discharge an average of 10 days later
Secondary outcomes (3)
Mean change in Subject Units of Distress (SUDS) from pre- to post-VR
This is a commonly used scale of 0 to 10 for measuring the subjective intensity of anxiety currently experienced by an individual. Scores range from 0 to 10, with lower values indicating lower distress and higher values indicating higher distress.
Measured: Immediately before and after each intervention (use of VR), up to two times per week for duration of hospital stay (average 10 days)
Mean change in Subjective units of relaxation from pre-to post-VR
This scale is similar to SUDS, but asks patients to rate their subjective relaxation on a 0 to 10 scale. Scores range from 0 to 10, with lower values indicating lower relaxation and higher values indicating higher relaxation.
Measured: Immediately before and after each intervention (use of VR), up to two times per week for duration of hospital stay (average 10 days)
Mean change in General Anxiety Disorder-7 (GAD-7; Spitzer et al., 2006) from baseline to discharge
A 7-item, empirically validated, and gold-standard brief measure of global anxiety. Scores range from 0 to 21 with lower values indicating lower levels of anxiety and higher values indicating higher levels of anxiety.
Measured: Immediately before first intervention (use of VR) and at hospital discharge an average of 10 days later
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Mar 2022
- Study start6 May 2022
- Primary completion18 Aug 2023
- Study completion18 Aug 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AnxietyStudies of the same condition, open and under way.
- More trials run by Weill Medical College of Cornell UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 29 participants (actual)
Sponsor and investigators
- Lead sponsor
- Weill Medical College of Cornell University
- Sponsor type
- University, hospital or other
- Collaborators
- Brain & Behavior Research Foundation
- Responsible party
- Sponsor
- Investigators
- Michelle Pelcovitz, Principal investigator, Weill Cornell Psychiatry
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05291533
- Sponsor's protocol ID
- 19-06020347
- Status last verified
- Apr 2024
- First submitted
- 2 Mar 2022
- Last updated
- 23 Apr 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Patient Experiences With Virtual Reality Mindfulness Skills Training
- ClinicalTrials.gov ID
- NCT05291533
- Acronym / sponsor ID
- 19-06020347
- Conditions
- Anxiety, Distress, Emotional
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 29 participants (actual)
- Lead sponsor
- Weill Medical College of Cornell UniversityUniversity, hospital or other
- Collaborators
- Brain & Behavior Research Foundation
- Study start
- 6 May 2022 (actual)
- Primary completion
- 18 Aug 2023 (actual)
- Study completion
- 18 Aug 2023 (actual)
- First posted
- 22 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to assess acceptability and preliminary efficacy of an intervention being administered clinically, a virtual reality (VR) mindfulness program. It is hypothesized that patients will find VR mindfulness an acceptable intervention and that it will reduce symptoms of anxiety.
Detailed description
This pilot study proposes to assess acceptability and preliminary efficacy of an intervention being administered clinically, a virtual reality (VR) mindfulness program. Acceptability and preliminary efficacy will be determined by 1) patient feedback on their satisfaction with the intervention evaluated by the Client Satisfaction Questionnaire-8 (CSQ-8); 2) changes in acute subjective anxiety before and after using the program; 3) changes in subjective relaxation before and after using the program; 4) changes in global anxiety at referral to psychology and just prior to discharge; Any patient on units with access to this VR program who are referred for a psychological evaluation will have the opportunity to engage in the VR intervention.
Overall Design:
This study is an open trial evaluating the acceptability and efficacy of a VR mindfulness program being clinically implemented to address acute anxiety in patients admitted to medical and rehabilitation inpatient units.
VR Mindfulness Program:
Participants referred for a psychological or neuropsychological evaluation will have the opportunity to complete the study. A study staff member who is not the evaluating clinician will approach the patient to inquire about their interest in the study and conduct the informed consent process. Patients are typically referred for a psychological evaluation based on acute anxiety observed by staff or reported by the patient. The evaluating psychologist will collaborate with treatment team to make a clinical determination about whether VR mindfulness is indication (see exclusion criteria below). If it is determined that the patient could benefit from the VR intervention, a VR team member will facilitate the administration of a self-report measure on anxiety (GAD-7), obtain subjective ratings of anxiety and relaxation, and then administer the 5-minute VR mindfulness intervention. After patient's completion of the intervention, the VR team member will repeat the measures of subjective anxiety and relaxation. This procedure will be repeated as-needed (determined by clinical team) or up to three times per week based on patient preference and staff availability. The CSQ-8 will be administered after the patient's first use of VR mindfulness and again the day before discharge, if the patient opted to use repeatedly. The study team will re-administer the GAD-7 on the day prior to the patient's discharge.
Study-specific procedures:
Upon determination by the clinical and study team that a patient is an appropriate candidate for VR mindfulness, the patient will be informed of the opportunity to participate in the study. It will be made clear to the patient that participation in the study is voluntary and will have no impact on their current or future access to care at NYP/WCM. If they agree they will undergo the informed consent process.
Scientific Rationale for Study Design:
This is an open trial to determine acceptability and efficacy of using VR mindfulness to address acute anxiety in varied clinical settings. This intervention is already being implemented clinically, this study seeks to assess acceptability and provide preliminary data on efficacy of this intervention. No control is being used at this time.
- Subject Selection
Subjects will be patients admitted to medical and rehabilitation inpatient units at NYP/WCM.
Recruitment:
Patients are identified by their clinical team during their inpatient admission as appropriate for the VR mindfulness intervention to address acute anxiety.
- Registration Procedures
Subjects will be registered within the WRG-CT as per the standard operating procedure for Subject Registration.
- Study Procedures Upon determination by the treatment team and VR team member that a patient is an appropriate candidate for VR mindfulness, the patient will be informed of the opportunity to participate in the study. It will be made clear to the patient that participation in the study is voluntary and will have no impact on their current or future access to care at NYP/WCM or their ability to participate in the VR mindfulness intervention. If they agree they will undergo the informed consent process.
Measures: Listed in the "Outcome Measures" section
Study intervention:
The study is seeking to evaluate the feasibility and preliminary efficacy of a VR mindfulness intervention. The VR program combines immersive, 3D visuals and audio with mindfulness skills practice. The program is designed to train participants you to calm their bodied and minds and its use is designed to enhance mindfulness practice. VR is a platform that has been used for a variety of applications, including gaming, entertainment, education and training.
Study duration, withdrawal and discontinuation:
Subjects will complete study procedures at least one time, with additional uses determined by need (decided by clinical team) or patient preference (up to three times per week based on staff availability). They will be followed for the duration of their admission. Study participation ends when they are discharged or are no longer eligible to use VR. Participants are free to withdraw from participation in the study at any time upon request.
An investigator may discontinue or withdraw a participant from the study for the following reasons:
- Significant study intervention non-compliance
- If any clinical adverse event (AE) or other medical condition or situation occurs such that continued participation in the study would not be in the best interest of the participant
- If the participant meets an exclusion criterion (either newly developed or not previously recognized) that precludes further study participation
- Participant unable to participate in VR mindfulness intervention
The reason for participant discontinuation or withdrawal from the study will be recorded on the Case Report Form (CRF). Subjects who sign the informed consent form and do not receive the study intervention may be replaced. Subjects who sign the informed consent form and receive the study intervention, and subsequently withdraw, or are withdrawn or discontinued from the study will be replaced.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients using VR Mindfulness Program | Other | Other: Virtual Reality (VR) Mindfulness ProgramParticipants are inpatients on any NYP/WCM unit that use VR mindfulness programs; any patient referred for a psychological or neuropsychological evaluation by their treatment team will have the opportunity to complete the VR program. The study is seeking to evaluate the feasibility and preliminary efficacy of the VR mindfulness intervention. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Referred to psychology/neuropsychology
- Identified by treatment team for use of VR mindfulness intervention
- Able to provide informed consent or assent
- Patient is over the age of 18
Key exclusion criteria (3 listed)
- Has not engaged in VR mindfulness intervention.
- Determination by clinical team that patient cannot or would not benefit from participation in VR.
- Reasons may include history of severe motion sickness or seizures, history of destruction of property, visual disturbance, vertigo, and cognitive impairment, delirium, and current or past diagnosis of a psychotic disorder
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Virtual Reality (VR) Mindfulness ProgramThe VR program combines immersive, 3D visuals and audio with mindfulness skills practice. The program is designed to train participants you to calm their bodied and minds and its use is designed to enhance mindfulness practice. VR is a platform that has been used for a variety of applications, including gaming, entertainment, education and training. | Other | Patients using VR Mindfulness Program |
Primary outcome
Change in composite score on Client Satisfaction Questionnaire-8 (CSQ-8; Attkisson & Zwick, 1982)
Time frame: Immediately after first intervention (use of VR) and at hospital discharge an average of 10 days later
An 8-item, empirically validated measure of satisfaction with a clinical program. Scores therefore range from 8 to 32, with lower values indicating lower satisfaction and higher values indicating higher satisfaction.
3 secondary outcomes
Mean change in Subject Units of Distress (SUDS) from pre- to post-VR
Time frame: Immediately before and after each intervention (use of VR), up to two times per week for duration of hospital stay (average 10 days)
Mean change in Subjective units of relaxation from pre-to post-VR
Time frame: Immediately before and after each intervention (use of VR), up to two times per week for duration of hospital stay (average 10 days)
Mean change in General Anxiety Disorder-7 (GAD-7; Spitzer et al., 2006) from baseline to discharge
Time frame: Immediately before first intervention (use of VR) and at hospital discharge an average of 10 days later
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Apr 2024.
- Individual participant dataSharing planned: No
Related trials for Anxiety
Recruiting
The Effect of Using Nature Sounds and Virtual Reality During the Non-Stress Test
Pregnancy - Prenatal Testing
Recruiting
Effect of Box Breathing Before Chest Tube Removal After Open-Heart Surgery
Open-Heart Surgery
Active, not recruitingPhase 4
Neural Circuit Effects of Ketamine in Depression
Major Depressive Disorder
Recruiting
A Study of a One-Time Counseling Session to Help Reduce Depression, Anxiety, and Distress in People With Cancer
Breast Cancer
Not yet recruitingObservational study
Media Use, Anxiety, Sedation, and Recovery in Children Having Upper GI Endoscopy
Anesthesia, Anxiety
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michelle Pelcovitz principal investigator
Weill Cornell Psychiatry
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Virtual Reality (VR) Mindfulness Program in people with Anxiety and Distress, Emotional, run by Weill Medical College of Cornell University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in composite score on Client Satisfaction Questionnaire-8 (CSQ-8; Attkisson & Zwick, 1982) (time frame: Immediately after first intervention (use of VR) and at hospital discharge an average of 10 days later). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Apr 2024.